Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
News
These were the 40 worst performing small and large capped ASX stocks in 2022
Health & Biotech
ASX Health Stocks: NSB files patent in Australia, Cronos ships one-millionth medicinal cannabis unit
News
ASX Large Caps: Shares up 1.3pc as RBA turns knob up 25bp; house prices down again
Health & Biotech
ASX Biotech Stocks: Nuheara secures historic FDA clearance for its over-the-counter hearing aid
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Small caps robbed, beaten left on side of road and hit by oncoming traffic, down 4.2%
News
Top 10 at 10: This is a pretty big lithium deal
News
ASX Large Caps: Gold miners lead selloff as high USD and rates test gold price; Whitehaven at all time high
Health & Biotech
ASX Health Stocks: Telix and Imugene keep making progress on cancer studies
Health & Biotech
ASX Health Stocks: Polynovo leaps 12pc after coming out of trading halt, gets FDA approval
News
Short & Caught: Popular lithium plays among most shorted ASX stocks
News
Market Highlights: Wall Street jumps good, Imugene raises hard and 5 ASX small caps to watch on Tuesday
Health & Biotech
ASX Health Stocks: Invion proves photodynamic therapy is effective against the Zika virus
Health & Biotech
ASX Health Stocks: Pharmaxis gets $5m to fund groundbreaking collaboration study of lead drug PXS‐4728
Health & Biotech
Here’s what biotech Imugene needs to do before it can become a multibagger again
Experts
ScoPo’s Powerplays: Taps on again with ASX health stocks in BIG capital raises
News